Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04086745 · ClinicalTrials.gov registry record · Phase 4
A Study of Baricitinib in Participants With Rheumatoid Arthritis
A Phase 4 study of Rheumatoid Arthritis, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,317
- Enrollment target
- 20
- Study locations
NCT04086745: Completed Phase 4 study of Rheumatoid Arthritis, sponsored by Eli Lilly and Company.
NCT04086745 is a Phase 4 study of Rheumatoid Arthritis that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,317 participants, below the 4,684-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04086745, a Phase 4 study of Rheumatoid Arthritis, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,317 participants
- Enrollment target
- 20
- Study locations
Study Summary
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Primary Outcome
Time from first dose of study treatment to first event of VTE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/Body Mass Index (BMI) combination, prior inadequate response or intolerance to a TNF inhibitor, and geographi
Conditions Studied
Interventions
- DRUG Baricitinib
- DRUG TNF Inhibitor
Study Locations (20)
California
- Providence St. Joseph's Medical Center - Burbank
- Hope Clinical Research, Inc. - Canoga Park
- Medvin Clinical Research - Covina - Covina
- TriWest Research Associates LLC - El Cajon
- Newport Huntington Med Grp - Huntington Beach
- BioSolutions Clinical Research Center - La Mesa
- Valerius Medical Group and Research Center of Greater Long Beach - Los Alamitos
- R. Srinivasan, M.D., Inc. dba Monterey Park Medical Center - Monterey Park
- ACRC Studies - Poway
- Desert Medical Advances - Rancho Mirage
- Purushotham & Akther Kotha MD Inc - San Diego
- East Bay Rheumatology Medical Group, Inc - San Leandro
- Providence Medical Foundation - Santa Rosa
- Dan La, MD Inc - Tujunga
Arizona
- Arizona Research Clinic PLLC - Chandler
- Arizona Arthritis & Rheumatology Associates, P. C. - Mesa
- Arizona Arthritis & Rheumatology Research - Paradise Valley
- Sun Valley Arthritis Center, LTD - Peoria
- Arizona Arthritis & Rheumatology Associates - Phoenix
Arkansas
- Arthritis and Rheumatism Associates - Jonesboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,317 participants |
| Start Date | 2020-02-14 |
| Est. Completion | 2025-05-19 |
| Phase | Phase 4 |
What the finished NCT04086745 record still lists
NCT04086745 is an interventional study that assigns participants to a tested intervention. Its 1,317 participants enrollment target places it among the larger protocols in the corpus, below the 4,684-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Baricitinib is the first listed.
NCT04086745 names 20 study sites across 3 states, led by California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT04086745 about?
NCT04086745 is a clinical study titled "A Study of Baricitinib in Participants With Rheumatoid Arthritis". This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
What is the current status of trial NCT04086745?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,317 participants. The study started on 2020-02-14. Estimated completion is 2025-05-19.
What conditions does trial NCT04086745 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT04086745?
The interventions under investigation include: Baricitinib (DRUG), TNF Inhibitor (DRUG).
Who is sponsoring clinical trial NCT04086745?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04086745 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04086745's enrollment target sits among peer trials
1,317 17th of 197 higher than 181 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NSAIDs vs. Coxibs in the Presence of Aspirin
RECRUITING · Phase 4
-
Improving Bone Health Among Rheumatoid Arthritis (RA) Patients on Chronic Glucocorticoids
COMPLETED · Phase 4
-
A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis
COMPLETED · Phase 4
-
Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis
COMPLETED · Phase 4
-
IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
COMPLETED · Phase 4
-
Centocor Microarray Study of Patients
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05762302 · 1,316 participants · NA
The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)
- NCT07144800 · 1,319 participants · NA
Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)
- NCT06557005 · 1,320 participants · NA
Facilitated Transitions From Postpartum to Primary Care Coordination for People With Chronic Conditions
- NCT07213908 · 1,320 participants · NA
Comparing Two School-Based Sleep Health Interventions To Promote Sleep Quality in Youth
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI